Literature DB >> 17011696

White blood cell count as a predictor of the severity of sickle cell disease during pregnancy.

Michail Litos1, Ippokratis Sarris, Susan Bewley, Paul Seed, Iheanyi Okpala, Eugene Oteng-Ntim.   

Abstract

OBJECTIVE: Increasing epidemiological evidence implicates leukocytosis as a major risk factor for poor outcome in non-pregnant sickle cell disease (SCD) patients. The aim of this study was to investigate whether steady-state white blood cell (WBC) count can predict SCD-related problems in pregnancy.
DESIGN: Retrospective observational study of 40 SCD pregnant women who had their antenatal care at Guy's & St Thomas' NHS Trust, London. Twenty-six women developed clinical complications related to SCD during their pregnancy (painful crisis, chest symptoms, infections, severe anaemia requiring blood transfusion, pre-eclampsia, and/or thromboembolism) and 14 remained asymptomatic. The steady-state leukocyte counts early in pregnancy were compared between the two groups and receiver operator characteristics (ROC) curve was plotted for different values of WBC.
RESULTS: Compared to asymptomatic patients, women who developed SCD-related complications had significantly higher total WBC count [11.2 x 10(9)L(-1) (SD 3.22) versus 8 x 10(9)L(-1) (2.8), p<0.01], higher lymphocyte count [3 x 10(9)L(-1) (1.62) versus 1.6 x 10(9)L(-1) (0.65), p<0.01] and higher monocyte count [0.8 x 10(9)L(-1) (0.47) versus 0.4 x 10(9)L(-1) (0.21), p<0.01]. The neutrophil count showed a similar trend but the difference did not reach statistical significance [6.6 x 10(9)L(-1) (2.29) versus 5.7 x 10(9)L(-1) (2.15), p=0.22]. The area under the ROC curve was 74% (95% CI: 56-92).
CONCLUSION: WBC count early in pregnancy was significantly higher in women who subsequently developed clinical problems related to SCD. The WBC may be used as a predictor of the severity of SCD in pregnancy.

Entities:  

Mesh:

Year:  2006        PMID: 17011696     DOI: 10.1016/j.ejogrb.2006.08.009

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  9 in total

Review 1.  The paradox of the neutrophil's role in tissue injury.

Authors:  George B Segel; Marc W Halterman; Marshall A Lichtman
Journal:  J Leukoc Biol       Date:  2010-11-19       Impact factor: 4.962

2.  Complications in pregnant women with sickle cell disease.

Authors:  Kim Smith-Whitley
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

3.  Hemoglobin F as a predictor of health-related quality of life in children with sickle cell anemia.

Authors:  Mohamed-Rachid Boulassel; Amira Al-Badi; Mohamed Elshinawy; Juhaina Al-Hinai; Muna Al-Saadoon; Zahra Al-Qarni; Hammad Khan; Rizwan Nabi Qureshi; Yasser Wali
Journal:  Qual Life Res       Date:  2018-10-22       Impact factor: 4.147

4.  Excess risk of maternal death from sickle cell disease in Jamaica: 1998-2007.

Authors:  Monika R Asnani; Affette M McCaw-Binns; Marvin E Reid
Journal:  PLoS One       Date:  2011-10-24       Impact factor: 3.240

5.  Telomere length correlates with disease severity and inflammation in sickle cell disease.

Authors:  Marina Pereira Colella; Barbara A Santana; Nicola Conran; Vinicius Tomazini; Fernando F Costa; Rodrigo T Calado; Sara T Olalla Saad
Journal:  Rev Bras Hematol Hemoter       Date:  2017-03-11

6.  The prevalence of abnormal leukocyte count, and its predisposing factors, in patients with sickle cell disease in Saudi Arabia.

Authors:  Anwar E Ahmed; Yosra Z Ali; Ahmad M Al-Suliman; Jafar M Albagshi; Majid Al Salamah; Mohieldin Elsayid; Wala R Alanazi; Rayan A Ahmed; Donna K McClish; Hamdan Al-Jahdali
Journal:  J Blood Med       Date:  2017-10-25

7.  OcclusionChip: A functional microcapillary occlusion assay complementary to ektacytometry for detection of small-fraction red blood cells with abnormal deformability.

Authors:  Yuncheng Man; Ran An; Karamoja Monchamp; Zoe Sekyonda; Erdem Kucukal; Chiara Federici; William J Wulftange; Utku Goreke; Allison Bode; Vivien A Sheehan; Umut A Gurkan
Journal:  Front Physiol       Date:  2022-08-25       Impact factor: 4.755

8.  Safety and efficacy of plerixafor dose escalation for the mobilization of CD34+ hematopoietic progenitor cells in patients with sickle cell disease: interim results.

Authors:  Farid Boulad; Tsiporah Shore; Koen van Besien; Caterina Minniti; Mihaela Barbu-Stevanovic; Sylvie Wiener Fedus; Fabiana Perna; June Greenberg; Danielle Guarneri; Vijay Nandi; Audrey Mauguen; Karina Yazdanbakhsh; Michel Sadelain; Patricia A Shi
Journal:  Haematologica       Date:  2018-02-01       Impact factor: 9.941

9.  Standardized microfluidic assessment of red blood cell-mediated microcapillary occlusion: Association with clinical phenotype and hydroxyurea responsiveness in sickle cell disease.

Authors:  Yuncheng Man; Erdem Kucukal; Ran An; Allison Bode; Jane A Little; Umut A Gurkan
Journal:  Microcirculation       Date:  2021-01-09       Impact factor: 2.628

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.